<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413944</url>
  </required_header>
  <id_info>
    <org_study_id>BnaiZionMC</org_study_id>
    <nct_id>NCT02413944</nct_id>
  </id_info>
  <brief_title>Standardized 1µg Adrenocorticotropic Hormone Stimulation Test, and Salivary Cortisol Concentration During the Test</brief_title>
  <official_title>Standardized Protocol for 1µg Adrenocorticotropic Hormone (ACTH) Stimulation Test, Minimizing Technical Issues That Could Influence Test Accuracy; and Determining Salivary Free Cortisol Concentration in Healthy Controls During the Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bnai Zion Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bnai Zion Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objectives: First, to determine whether intravenous injection of 1 mcg&#xD;
      adrenocorticotropic hormone (ACTH) through short cannula, in healthy participants, provides&#xD;
      reliable results of cortisol response, and whether this method would replace the conventional&#xD;
      technique of injecting ACTH by a needle directly into a peripheral vein. Secondly, to&#xD;
      determine salivary free cortisol concentration during the test in healthy controls.&#xD;
&#xD;
      Rationale of study: Intravenous injection of synthetic ACTH1-24 concentration through venous&#xD;
      short cannula appears to be feasible and simple method. On the other hand, injection of&#xD;
      ACTH1-24 by a needle directly into peripheral vein, is not infrequently complicated by&#xD;
      technical problems in subjects with challenging veins. The investigators suppose that, both&#xD;
      methods would have the same yield in predicting cortisol response.&#xD;
&#xD;
      Salivary free cortisol test has an evolving importance in assessing the adrenal function.&#xD;
      This test would be reliable for use in low dose ACTH stimulation (1 mcg) test. The&#xD;
      investigators will examine the concentration of salivary free cortisol during ACTH&#xD;
      stimulation test, in order to determine level range in normal controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 20 healthy participants of both sexes, aged 18-70 years, that have no&#xD;
      clinical suspicion of hypoadrenalism, or any active medical condition or treatment that might&#xD;
      alter blood cortisol levels. Pregnant women and patients whose medical or mental condition&#xD;
      precludes obtaining informed consent will be excluded.&#xD;
&#xD;
      In the morning of the first visit, 1 mcg of ACTH1-24 will be injected directly into a&#xD;
      peripheral vein. Blood and salivary samples will be drawn before injection, and 30 minutes&#xD;
      after. Salivary cortisol will be drawn also 60 minutes after injection. At least two days&#xD;
      later, in the morning of the second visit, 1 mcg of ACTH1-24 will be injected through short&#xD;
      cannula in a peripheral vein, followed by injection of 5 ml of normal saline. Blood and&#xD;
      salivary samples will be drawn before injection, and 30 minutes after. Salivary cortisol will&#xD;
      be drawn also 60 minutes after injection. Blood cortisol results and salivary free cortisol&#xD;
      results will be compared between tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum cortisol concentrations during intravenous injection of 1 mcg adrenocorticotropic hormone through short cannula and during direct intravenous injection, in healthy participants.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Salivary free cortisol concentrations during intravenous injection of 1 mcg adrenocorticotropic hormone through short cannula and during direct intravenous injection, in healthy participants.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACTH stimulation test</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ACTH stimulation test</intervention_name>
    <description>ACTH stimulation test</description>
    <arm_group_label>healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy participants of both sexes&#xD;
&#xD;
          -  aged 18-70 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any clinical suspicion of hypoadrenalism, or any active medical condition or treatment&#xD;
             that might alter blood cortisol levels&#xD;
&#xD;
          -  pregnant women and patients whose medical or mental condition precludes obtaining&#xD;
             informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard Saiegh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bnai Zion Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bnai Zion MC</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>April 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bnai Zion Medical Center</investigator_affiliation>
    <investigator_full_name>leonard.saiegh</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

